Back to mobile site

Jazz Pharmaceuticals acquires Actio Biosciences for $820 million

September 15, 2026 9:01 AM EDT Send to a Friend
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has completed its acquisition of privately-held Actio Biosciences, Inc. for $820 million upfront, making Actio ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login